These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9346859)

  • 1. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
    Kaumaya PT; Conrad SF; DiGeorge AM; Lairmore MD
    Leukemia; 1995 Oct; 9 Suppl 1():S133-8. PubMed ID: 7475306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S; Reuben JS; Streilein RD; Palker TJ
    J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
    Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
    Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
    Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
    J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
    Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
    J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.
    Lairmore MD; Lal RB; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):117-22. PubMed ID: 9346842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
    Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
    Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies.
    Sundaram R; Lynch MP; Rawale SV; Sun Y; Kazanji M; Kaumaya PT
    J Biol Chem; 2004 Jun; 279(23):24141-51. PubMed ID: 15060075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.